Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Quantitative V gene–targeted T cell receptor sequencing as a biomarker in type 1 diabetes
Laurie G. Landry, Kristen L. Wells, Amanda M. Anderson, Kristen R. Miller, Kenneth L. Jones, Aaron W. Michels, Maki Nakayama
Laurie G. Landry, Kristen L. Wells, Amanda M. Anderson, Kristen R. Miller, Kenneth L. Jones, Aaron W. Michels, Maki Nakayama
View: Text | PDF
Research Article Immunology

Quantitative V gene–targeted T cell receptor sequencing as a biomarker in type 1 diabetes

  • Text
  • PDF
Abstract

Developing biomarkers to quantitatively monitor disease-specific T cell activity is crucial for assessing type 1 diabetes (T1D) progression and evaluating immunotherapies. This study presents an approach using V gene–targeted sequencing to quantify T cell receptor (TCR) clonotypes as biomarkers for pathogenic T cells in T1D. We identified “public” TCR clonotypes shared among multiple nonobese diabetic (NOD) mice and human organ donors, with a subset expressed exclusively by islet-antigen-reactive T cells in those with T1D. Employing V gene–targeted sequencing of only TCRs containing TRAV16/16D allowed quantitative detection of the public islet-antigen-reactive TCR clonotypes in peripheral blood of NOD mice. Frequencies of these public TCR clonotypes distinguished prediabetic NOD mice from those protected from diabetes. In human islets, public TCR clonotypes identical to preproinsulin-specific clones were exclusively found in T1D donors. This quantifiable TCR sequencing approach uncovered public, disease-specific clonotypes in T1D, providing biomarker candidates to monitor pathogenic T cell frequencies in blood for assessing disease activity and therapeutic response.

Authors

Laurie G. Landry, Kristen L. Wells, Amanda M. Anderson, Kristen R. Miller, Kenneth L. Jones, Aaron W. Michels, Maki Nakayama

×

Figure 1

Landscape of TCR repertoires in the islets of NOD mice.

Options: View larger image (or click on image) Download as PowerPoint
Landscape of TCR repertoires in the islets of NOD mice.
TCR α and β chai...
TCR α and β chain clonotypes expressed by T cells in the islets of 7 prediabetic adult NOD mice were determined and analyzed for frequencies and sharing between individual mice. (A) Percentages of unique α and β clonotypes that account for top 50% ranked sequence reads in each mouse are plotted. Smaller percentages imply that TCR repertoires are more deviated toward particular clonotypes. (B) Percentages of TCR α (left panel) and β clonotypes (right panel) detected from different numbers of mice are plotted. Over 95% of clonotypes were detected from only a single mouse. (C) Frequencies of TCR α (left panel) and β clonotypes (right panel) detected from different numbers of mice are shown in violin plots. There were no β clonotypes that were detected from 6 or 7 mice. There was a significant difference between number of mice sharing a clonotype and average frequency of clonotypes (overall F test P < 0.0001 for both α and β clonotypes assessed by 1-way ANOVA with Tukey’s honestly significant difference [HSD] test).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts